Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943450 | 1.00 | KMT2A (0.36) | KMT2AMGLLLTA4HLMNAPOLB | |
| SCHEMBL8802399 | 0.81 | CES2 (0.43) | KMT2AMGLLLTA4HLMNAPOLB | |
| SCHEMBL2946859 | 0.79 | MTOR (0.40) | KMT2ALMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL2946856 | 0.79 | MTOR (0.40) | KMT2ALMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL2944264 | 0.78 | LTA4H (0.49) | KMT2ALTA4HLMNAMAPK7NPC1 | |
| SCHEMBL2947698 | 0.78 | LTA4H (0.33) | LTA4HLMNACYP17A1CYP3A4CYP19A1 | |
| SCHEMBL5708704 | 0.75 | KMT2A (0.36) | KMT2APOLBMAPK7SMN1; SMN2 | |
| SCHEMBL13234361 | 0.73 | RAB9A (0.45) | KMT2APOLBHTTSMN1; SMN2CYP17A1 | |
| SCHEMBL15897828 | 0.67 | KDM1A (0.35) | NPC1RAB9A | |
| SCHEMBL30204833 | 0.67 | ESR1 (0.42) | KMT2AMGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750026-B2 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1709028-B1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-03-08 | — | — | US | disclosed |
| EP-1709028-A1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073217-A1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK7, MAPKAPK2 | KMT2A 4185/4885MGLL 4050/4885LTA4H 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.